5976-74-9

Upstream product

• 53-16-7 Estrone 
• 50-06-6 phenobarbital 
• 5976-73-8 2-nitroestrone 

Downstream Products

• 14984-42-0 4-Aminoestrone 
• 96607-56-6 4-nitro<(1-phenyl-1H-tetrazol-5-yl)oxy>estra-1,3,5(10)-trien-17-one 
• 80082-66-2 4-nitroestrone 3-O-(2-hydroxyethyl) ether 
• 80082-67-3 4-nitroestrone 3-O-(3-hydroxypropyl) ether 
• 6936-94-3 4-Nitroestratriene-3,17beta-diol 
• 83873-02-3 (5bS,7aS,10aS,10bR)-7a-Methyl-2-phenylamino-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-00-1 (5bS,7aS,10aS,10bR)-2-Benzylamino-7a-methyl-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-04-5 (5bS,7aS,10aS,10bR)-7a-Methyl-2-m-tolylamino-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-06-7 (5bS,7aS,10aS,10bR)-7a-Methyl-2-p-tolylamino-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-10-3 (5bS,7aS,10aS,10bR)-2-(4-Fluoro-phenylamino)-7a-methyl-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-12-5 (5bS,7aS,10aS,10bR)-2-(4-Chloro-phenylamino)-7a-methyl-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-14-7 (5bS,7aS,10aS,10bR)-2-(4-Bromo-phenylamino)-7a-methyl-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 83873-08-9 (5bS,7aS,10aS,10bR)-2-(4-Methoxy-phenylamino)-7a-methyl-5b,6,7,7a,9,10,10a,10b,11,12-decahydro-3-oxa-1-aza-dicyclopenta[a,i]phenathren-8-one 
• 14846-63-0 4-nitro-3-benzyloxyestra-1,3,5-triene-17-one 

Relevant academic research and scientific papers

Synthesis and conversion of primary and secondary 2-aminoestradiols into A-ring-integrated benzoxazolone hybrids and theirin vitroanticancer activity

Hybrid systems are often endowed with completely different and improved properties compared to their parent compounds. In order to extend the chemical space toward sterane-based molecular hybrids, a number of estradiol-derived benzoxazol-2-ones with combined aromatic rings were synthesizedviathe corresponding 2-aminophenol intermediates. 2-Aminoestradiol was first prepared from estrone by a two-step nitration/reduction sequence under mild reaction conditions. Subsequent reductive aminations with different arylaldehydes furnished secondary 2-aminoestradiol derivatives in good yields. The proton dissociation processes of the aminoestradiols were investigated in aqueous solution by UV-visible spectrophotometric titrations to reveal their actual chemical forms at physiological pH. The determined pK1and pK2values are attributed to the+NH3or+NH2R and OH moieties, and both varied by the different R substituents of the amino group. Primary and secondary 2-aminoestradiols were next reacted with carbonyldiimidazole as a phosgene equivalent to introduce a carbonyl group with simultaneous ring-closure to give A-ring-fused oxazolone derivatives in high yields. The novel aminoestradiols and benzoxazolones were subjected toin vitrocytotoxicity analysis and were found to exert cancer cell specific activity.

Microwave-induced surface-mediated highly efficient regioselective nitration of aromatic compounds: Effects of penetration depth

Surface mediated highly regioselective nitration of aromatic compounds under diverse microwave-induced conditions was investigated in this work. The effects of the penetration depth of the surfaces were found to be more crucial than other dielectric parameters. Despite significant progress of microwave-induced reactions, no reports have examined the penetration depth of the surfaces used in these processes.

COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF ANDROGEN-MEDIATED DISEASE

Provided herein are steroid sulfatase inhibitor compounds and androgen receptor inhibitor compounds that can be useful in, for example, the treatment of cancers such as prostate cancer and breast cancer. Pharmaceutical compositions and kits including the

A-ring substituted 17β-arylsulfonamides of 17β-aminoestra-1,3,5(10)-trien-3-ol as highly potent reversible inhibitors of steroid sulfatase

Steroid sulfatase (STS) catalyzes the hydrolysis of the sulfate ester group in biologically inactive sulfated steroids to give biologically active steroids. Inhibitors of STS are considered to be potential therapeutics for treating hormone-dependent cancers such as ER+ breast cancer. A series of 4-substituted 17β-arylsulfonamides of 17β-aminoestra-1,3,5(10)-trien-3-ol were prepared and examined as STS inhibitors. The presence of a NO2 or Br at the 2-position of the A-ring resulted in a decrease in potency compared to their A-ring-unsubstituted counterparts. However the presence of a nitro group or fluorine atom at the 4-position of the A-ring resulted in an increase in potency and one of these compounds exhibited a Kiapp value of 1 nM. Modeling studies provided insight into how these compounds interact with active site residues. The anti-proliferative activity of the 3′-Br, 3′-CF3, 4-NO2-3′-Br and 4-NO2-3′-CF3 derivatives were examined using the NCI 60-cell-line panel and found to have mean graph midpoint values of 1.9-3.4 μM.

Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors

Estrone sulfamate (EMATE) is a potent irreversible inhibitor of steroid sulfatase (STS). In order to further expand SAR, the compound was substituted at the 2- and/or 4-positions and its 17-carbonyl group was also removed. The following general order of p

17ALPHA-SUBSTITUTED STEROIDS AS SYSTEMIC ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS

Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

TARGET-ORIENTED CHEMOTHERAPY FOR TREATING TUMORS OF THE SEXUAL ORGANS

The invention relates to dialkyltriazene-supporting estrogens and antiestrogens that are suited for use as chemotherapeutic drugs for treating carcinomas of the sexual organs of humans and animals.

Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use

Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have the structural formula (I) wherein r1 is an optional double bond, R1 and R2 are selected from the group consisting of hydrogen and lower alky, or together form a cy

Surface-mediated highly efficient regioselective nitration of aromatic compounds by bismuth nitrate

Montmorillonite impregnated with bismuth nitrate was found to be an excellent reagent for aromatic nitration in high yield. (C) 2000 Elsevier Science Ltd.

The behaviour of some estrogens in the nitration process II. A comparative study of 18-crown-6 ether effect on estrone nitration with NO2, NO+2, HNO2 and NO-2 species

The estrone 1 conversion by nitration and the percentage of nitroderivatives obtained, i.e. 2-nitroestrone 2, 4-nitroestrone 3 and 2,4-dinitroestrone 4, depend on the nitration procedure used (through NO+2, HNO2, NO2 gas or NO-2 anion in the presence of crown ether 18C6, respectively). The dinitroderivative 4 was obtained only in the nitration process by means of NO2 gas. Estrone 1 was also nitrated with NO-2 anion in the presence of valinomycin antibiotic macrocyclic ionophore; the procedure was identical to that adopted for 18C6.